HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more
HBM HLDGS LTD DL-000025 (6XY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, HBM HLDGS LTD DL-000025 (6XY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
HBM HLDGS LTD DL-000025 - Net Assets Trend (None–None)
This chart illustrates how HBM HLDGS LTD DL-000025's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HBM HLDGS LTD DL-000025 (None–None)
The table below shows the annual net assets of HBM HLDGS LTD DL-000025 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to HBM HLDGS LTD DL-000025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
HBM HLDGS LTD DL-000025 Competitors by Market Cap
The table below lists competitors of HBM HLDGS LTD DL-000025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Awinic Technology Co Ltd
SHG:688798
|
$806.54 Million |
|
Hangzhou Cable
SHG:603618
|
$806.72 Million |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
$807.00 Million |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
$807.53 Million |
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
$805.92 Million |
|
Super Hi International Holding Ltd.
OTCGREY:SPHIF
|
$805.43 Million |
|
Loma Negra Compania Industrial Argentina SA
BA:LOMA
|
$805.39 Million |
|
PetroVietnam Drilling & Well Service Corp
VN:PVD
|
$805.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HBM HLDGS LTD DL-000025's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares HBM HLDGS LTD DL-000025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently HBM HLDGS LTD DL-000025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares HBM HLDGS LTD DL-000025's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HBM HLDGS LTD DL-000025 (6XY) | €- | N/A | N/A | $806.05 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |